Pharmacokinetics of intravenous omeprazole in children

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00194970PMID 7859807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Propranolol steady-state pharmacokinetics are unaltered by omeprazole

  2004cited by this paper
• Pharmacokinetics of various single intravenous and oral doses of omeprazole

  2004cited by this paper
• Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

  1993cited by this paper
• Efficacy and safety of omeprazole for severe gastroesophageal reflux in children.

  1993cited by this paper
• A study of the interaction between omeprazole and cyclosporine in renal transplant patients.

  1993cited by this paper
• Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients.

  1992cited by this paper
• Effectiveness and pharmacokinetics of omeprazole in children with refractory duodenal ulcer.

  1992cited by this paper
• Omeprazole Drug Interaction Studies

  1991cited by this paper
• Pharmacokinetics of Omeprazole and Metabolites Following Single Intravenous and Oral Doses of 40 and 80mg

  1990cited by this paper
• The effect of hemodialysis on omeprazole plasma concentrations in the anuric patient: a case report.

  1990cited by this paper
• The Pharmacokinetics of Omeprazole in Humans—A Study of Single Intravenous and Oral Doses

  1990cited by this paper
• Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring.

  1990cited by this paper
• Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinogenemia I in an infant.

  1990cited by this paper
• Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial.

  1990cited by this paper
• Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

  1990cited by this paper
• Omeprazole: pharmacokinetics and metabolism in man.

  1989influential reference
• Improved procedure for quantitation of omeprazole and metabolites using reversed-phase high-performance liquid chromatography.

  1988cited by this paper
• The anti‐secretory effect and pharmacokinetics of omeprazole in chronic liver disease

  1988cited by this paper
• Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.

  1988cited by this paper
• Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

  1987cited by this paper
• Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo.

  1987cited by this paper
• A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers.

  1986cited by this paper
• Pharmacokinetics and metabolism of omeprazole in man.

  1986cited by this paper
• Intravenous omeprazole: effect on 24-hour intragastric pH in duodenal ulcer patients.

  1986cited by this paper
• Pharmacokinetics of [14C] omeprazole in patients with impaired renal function

  1986cited by this paper
• Pharmacokinetics and metabolism of omeprazole in animals and man--an overview.

  1985cited by this paper
• Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

  1985cited by this paper
• Omeprazole inhibits oxidative drug metabolism

  1985cited by this paper
• Intravenous omeprazole rapidly raises intragastric pH.

  1985cited by this paper
• Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.

  1984cited by this paper
• Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

  1983cited by this paper

• Leveraging Omeprazole PBPK/PD Modeling to Inform Drug–Drug Interactions and Specific Recommendations for Pediatric Labeling

  2025influential citation
• Meta‐analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling

  2016cites this paper
• Clinical Pharmacology Studies in Critically Ill Children

  2016cites this paper
• Population Pharmacokinetics of Omeprazole in Critically Ill Pediatric Patients

  2014cites this paper
• Pharmacokinetics in children with liver disease : can ex vivo obtained population-specific CYP450 characteristics bridge the knowledge gap?

  2014cites this paper
• Pediatric pharmacokinetics: human development and drug disposition.

  2012cites this paper
• Evaluation of the effects of therapeutic hypothermia and cardiac arrest on specific cytochrome P450 isoform activity

  2011cites this paper
• The effect of inflammation on drug metabolism: a focus on pediatrics.

  2011cites this paper
• Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients

  2010cites this paper
• Interspecies Scaling for the Prediction of Drug Clearance in Children

  2010cites this paper
• DRUG MILK TO SERUM RATIO PREDICTION AND ONTOGENY OF CYP3A CLEARANCE PATHWAY AS A MODEL OF DRUG EXPOSURE IN THE DEVELOPING RAT

  2007influential citation
• Pharmacokinetics of Proton Pump Inhibitors in Children

  2005cites this paper
• The pharmacokinetics, CYP2C19 pharmacogenetics and psychomotor impairment of the centrally acting muscle relaxant carisoprodol

  2005cites this paper
• Neonatal Exposure to Drugs in Breast Milk

  2004cites this paper
• Omeprazole Disposition in Children following Single‐Dose Administration

  2003cites this paper
• Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors.

  2003cites this paper
• The Use of Proton Pump Inhibitors in Children

  2003cites this paper
• The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children.

  2003cites this paper
• Oméprazole dans le traitement des œsophagites peptiques de l'enfant

  2002cites this paper
• Gastroesophageal Reflux in Children

  2002cites this paper
• Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants: Part II

  2002cites this paper
• Approaches to Studying the Development of Drug Metabolism in Children

  2002cites this paper
• Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants Part I

  2002cites this paper
• A review of omeprazole use in the treatment of acid-related disorders in children.

  2001cites this paper
• Intravenous Omeprazole in Children: Pharmacokinetics and Effect on 24-Hour Intragastric pH

  2001cites this paper
• Pharmacokinetic Considerations in the Eradication of Helicobacter Pylori

  2000cites this paper
• Pharmacokinetics of orally administered omeprazole in children

  2000cites this paper
• Synergistic In Vitro Antimalarial Activity of Omeprazole and Quinine

  1999cites this paper
• A three-day course of intravenous omeprazole plus antibiotics for H. pylori-positive bleeding duodenal ulcer.

  1999cites this paper
• [Proton pump inhibitors in pediatrics].

  1999cites this paper
• Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

  1998cites this paper